Detalhe da pesquisa
1.
SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.
PLoS Biol
; 20(2): e3001531, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35143473
2.
SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.
Lancet Reg Health Am
; 16: 100390, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36408529